APRESOLINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APRESOLINE is an oral small-molecule tablet approved in 1953 by Novartis for cardiovascular indications. The drug's specific mechanism of action and approved indications are not detailed in available data, but it represents a legacy antihypertensive agent from the mid-20th century. It is formulated as a tablet for systemic absorption.
LOE Approaching
As LOE approaches, brand team size is likely contracting; focus shifts from growth to lifecycle extension and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on APRESOLINE offers limited growth potential given its LOE-approaching status and zero linked job openings; career value lies in lifecycle management expertise and legacy product stewardship. This role is best suited for professionals seeking stability rather than advancement or those building experience in mature product commercialization.
Brand ManagerMedical Science Liaison (MSL)
Worked on APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.